This finding has resulted in targeting dendritic cells (DCs) and macrophages for PD-L1 blockade to recover anti-tumor immunity [19,20], while the study of PD-L1+ neutrophils is still a minor field and has far less accumulated evidence than other myeloid cells. The gene discussed is CD274; the disease is neoplasm.